CI
HRTX icon

Cowen Inc’s Heron Therapeutics HRTX Stock Holding History

Cowen Inc’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-38,800
Closed -$1.04M – 304
2015
Q4 		$1.04M Sell
38,800
-21,200
-35% -$567K 0.08% 149
2015
Q3 		$1.26M Buy
+60,000
New +$2M 0.08% 133

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cowen Inc's HRTX Position: Q1 2016 in Review

Cowen Inc sold out of Heron Therapeutics (HRTX) in Q1 2016, closing a stake of 18,000 shares — an estimated $481K sold.

Cowen Inc first reported a position in HRTX in Q4 2015 and held it in 1 quarter. The position peaked at $481K in Q4 2015. 99 funds tracked by Wall St. Rank hold HRTX as of Q1 2016.

  • Cowen Inc reported no remaining Heron Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Cowen Inc sold 18,000 Heron Therapeutics shares in Q1 2016, an estimated $481K.
  • Cowen Inc first reported a position in Heron Therapeutics in Q4 2015 and held it in 1 quarter.
  • Cowen Inc's Heron Therapeutics position peaked at $481K in Q4 2015.
  • 99 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2016.

Based on Cowen Inc's 13F filing for Q1 2016, filed 16 May 2016.